Citadel Advisors
PYXS icon

Citadel Advisors’s Pyxis Oncology PYXS Stock Holding History

Citadel Advisors’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.2K Sell
14,700
-52,400
-78% -$100K ﹤0.01% 13176
2026
Q1 		$98K Sell
67,100
-8,400
-11% -$12.7K ﹤0.01% 12039
2025
Q4 		$86.8K Buy
+75,500
New +$266K ﹤0.01% 11744
2025
Q2 		– Sell
-19,500
Closed -$19.1K – 14582
2025
Q1 		$19.1K Sell
19,500
-22,000
-53% -$29.4K ﹤0.01% 13179
2024
Q4 		$64.7K Buy
41,500
+31,900
+332% +$92K ﹤0.01% 12080
2024
Q3 		$35.2K Buy
9,600
+600
+7% +$2.1K ﹤0.01% 12281
2024
Q2 		$29.8K Sell
9,000
-2,300
-20% -$9.67K ﹤0.01% 12282
2024
Q1 		$48.1K Buy
11,300
+9,200
+438% +$38.7K ﹤0.01% 12208
2023
Q4 		$3.78K Buy
+2,100
New +$3.6K ﹤0.01% 13560

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's PYXS Position: Q2 2026 in Review

Citadel Advisors reduced its Pyxis Oncology (PYXS) stake by 23% in Q2 2026, selling an estimated $26.6K and leaving 47,317 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #12394.

Citadel Advisors first reported a position in PYXS in Q4 2021 and has held it in 13 quarters since. The position peaked at $16.5M in Q4 2021. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Citadel Advisors held 47,317 shares of Pyxis Oncology worth $142K as of Q2 2026.
  • Citadel Advisors sold 13,932 Pyxis Oncology shares in Q2 2026, an estimated $26.6K.
  • Pyxis Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12394 holding.
  • Citadel Advisors first reported a position in Pyxis Oncology in Q4 2021 and has held it in 13 quarters since.
  • Citadel Advisors's Pyxis Oncology position peaked at $16.5M in Q4 2021.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.